Transmission of Variant Creutzfeldt-Jakob Disease Through Blood Transfusion and Plasma-Derived Products: A Narrative Review of Observed and Modeled Risks

Report for the Eighth Asian National Control Laboratory Network meeting in 2023: Self-sufficiency strategy of plasma-derived medicinal products and regulatory harmonisation

“…In response, Dr. In Soo Shin suggested that the should take the leadership in standardising vCJD-related donor deferral regulations, as many scientific studies support that the current risk of transmission of vCJD by blood and blood components is negligible [ [11] , [12] , [13] ]. Representatives from six countries also agreed on the need for international harmonisation of the standards, and Dr. Yuyun Siti Maryuningsih said that the WHO is monitoring this situation regarding blood safety and vCJD through expert consultations, harmonisation of related regulations is expected, and will try to further discuss this issue on the ECBS, if needed.…”